GLEEVEC vs TAGRISSO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. GLEEVEC and TAGRISSO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GLEEVEC	TAGRISSO
Rating	70/100	70/100
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	OSIMERTINIB MESYLATE
Manufacturer	Novartis	Astrazeneca
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Non-Small-Cell Lung Carcinoma

gleevec tagrisso

Rating

70/100

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

OSIMERTINIB MESYLATE

Manufacturer

Novartis

Astrazeneca

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Gleevec or Tagrisso?

Gleevec and Tagrisso are tied at 3.5 out of 5 by our independent rating.

What is the difference between Gleevec and Tagrisso?

Gleevec contains Imatinib Mesylate, while Tagrisso contains Osimertinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.